Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Supply, Demand and Key Producers, 2023-2029
The global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
PEG-modified drugs have the following advantages: improving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
PEG-modified drugs (recombinant proteins/polypeptides) refer to the formation of PEG-modified complexes by covalently linking polyethylene glycol molecules to recombinant proteins or polypeptide drugs. This modification can endow the drug with many beneficial properties, improving its pharmacological and biological properties.
This report studies the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for PEG-modified Drugs (Recombinant Proteins-Polypeptides), and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of PEG-modified Drugs (Recombinant Proteins-Polypeptides) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) total production and demand, 2018-2029, (K Units)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) total production value, 2018-2029, (USD Million)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) domestic production, consumption, key domestic manufacturers and share
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck Sharp & Dohme, Baxalta, Amgen, Roche, UCB S.A., Enzon, Horizon Pharma, Biogen and SunBio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World PEG-modified Drugs (Recombinant Proteins-Polypeptides) market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market, By Region:
1. How big is the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
2. What is the demand of the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
3. What is the year over year growth of the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
4. What is the production and production value of the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
5. Who are the key producers in the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
6. What are the growth factors driving the market demand?
PEG-modified drugs have the following advantages: improving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
PEG-modified drugs (recombinant proteins/polypeptides) refer to the formation of PEG-modified complexes by covalently linking polyethylene glycol molecules to recombinant proteins or polypeptide drugs. This modification can endow the drug with many beneficial properties, improving its pharmacological and biological properties.
This report studies the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for PEG-modified Drugs (Recombinant Proteins-Polypeptides), and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of PEG-modified Drugs (Recombinant Proteins-Polypeptides) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) total production and demand, 2018-2029, (K Units)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) total production value, 2018-2029, (USD Million)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) domestic production, consumption, key domestic manufacturers and share
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck Sharp & Dohme, Baxalta, Amgen, Roche, UCB S.A., Enzon, Horizon Pharma, Biogen and SunBio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World PEG-modified Drugs (Recombinant Proteins-Polypeptides) market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Jinyouli
- Xin Rui Bai
- Shenlida
- Jin Saizeng
- Pegbin
- Fulaimei
- Aido
- Nonmyeloid Malignancy
- Slow Growth in Children
- Viral Hepatitis
- Adult Type 2 Diabetes
- Others
- Merck Sharp & Dohme
- Baxalta
- Amgen
- Roche
- UCB S.A.
- Enzon
- Horizon Pharma
- Biogen
- SunBio
- Qilu Pharmaceutical
- Changchun Genescience Pharmaceutical
- Xiamen Amoytop Biotech
- Jiangsu Hengrui Pharmaceuticals
- Hansoh Pharmaceuticak Group
- CSPC Baike (Shandong) Biopharmaceutical
- Xiamen Sano banger Biotechnology
- Lunan Pharmaceutical Group
- Xiamen Amoytop Biotech
- JenKem Technology
1. How big is the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
2. What is the demand of the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
3. What is the year over year growth of the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
4. What is the production and production value of the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
5. Who are the key producers in the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Introduction
1.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Supply & Forecast
1.2.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value (2018 & 2022 & 2029)
1.2.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.2.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Pricing Trends (2018-2029)
1.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Region (Based on Production Site)
1.3.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Region (2018-2029)
1.3.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Region (2018-2029)
1.3.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2018-2029)
1.3.4 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.3.5 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.3.6 China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.3.7 Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Demand (2018-2029)
2.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption by Region
2.2.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption by Region (2018-2023)
2.2.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Forecast by Region (2024-2029)
2.3 United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.4 China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.5 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.6 Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.7 South Korea PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.8 ASEAN PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.9 India PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
3 WORLD PEG-MODIFIED DRUGS (RECOMBINANT PROTEINS-POLYPEPTIDES) MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Manufacturer (2018-2023)
3.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Manufacturer (2018-2023)
3.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Manufacturer (2018-2023)
3.4 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for PEG-modified Drugs (Recombinant Proteins-Polypeptides) in 2022
3.5.3 Global Concentration Ratios (CR8) for PEG-modified Drugs (Recombinant Proteins-Polypeptides) in 2022
3.6 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Overall Company Footprint Analysis
3.6.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Region Footprint
3.6.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Type Footprint
3.6.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Comparison
4.1.1 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Comparison
4.2.1 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Comparison
4.3.1 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers and Market Share, 2018-2023
4.4.1 United States Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value (2018-2023)
4.4.3 United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023)
4.5 China Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers and Market Share
4.5.1 China Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value (2018-2023)
4.5.3 China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023)
4.6 Rest of World Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Jinyouli
5.2.2 Xin Rui Bai
5.2.3 Shenlida
5.2.4 Jin Saizeng
5.2.5 Pegbin
5.2.6 Fulaimei
5.2.7 Aido
5.3 Market Segment by Type
5.3.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Type (2018-2029)
5.3.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type (2018-2029)
5.3.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Nonmyeloid Malignancy
6.2.2 Slow Growth in Children
6.2.3 Viral Hepatitis
6.2.4 Adult Type 2 Diabetes
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Application (2018-2029)
6.3.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application (2018-2029)
6.3.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Merck Sharp & Dohme
7.1.1 Merck Sharp & Dohme Details
7.1.2 Merck Sharp & Dohme Major Business
7.1.3 Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.1.4 Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Merck Sharp & Dohme Recent Developments/Updates
7.1.6 Merck Sharp & Dohme Competitive Strengths & Weaknesses
7.2 Baxalta
7.2.1 Baxalta Details
7.2.2 Baxalta Major Business
7.2.3 Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.2.4 Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Baxalta Recent Developments/Updates
7.2.6 Baxalta Competitive Strengths & Weaknesses
7.3 Amgen
7.3.1 Amgen Details
7.3.2 Amgen Major Business
7.3.3 Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.3.4 Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Amgen Recent Developments/Updates
7.3.6 Amgen Competitive Strengths & Weaknesses
7.4 Roche
7.4.1 Roche Details
7.4.2 Roche Major Business
7.4.3 Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.4.4 Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Roche Recent Developments/Updates
7.4.6 Roche Competitive Strengths & Weaknesses
7.5 UCB S.A.
7.5.1 UCB S.A. Details
7.5.2 UCB S.A. Major Business
7.5.3 UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.5.4 UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 UCB S.A. Recent Developments/Updates
7.5.6 UCB S.A. Competitive Strengths & Weaknesses
7.6 Enzon
7.6.1 Enzon Details
7.6.2 Enzon Major Business
7.6.3 Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.6.4 Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Enzon Recent Developments/Updates
7.6.6 Enzon Competitive Strengths & Weaknesses
7.7 Horizon Pharma
7.7.1 Horizon Pharma Details
7.7.2 Horizon Pharma Major Business
7.7.3 Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.7.4 Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Horizon Pharma Recent Developments/Updates
7.7.6 Horizon Pharma Competitive Strengths & Weaknesses
7.8 Biogen
7.8.1 Biogen Details
7.8.2 Biogen Major Business
7.8.3 Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.8.4 Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Biogen Recent Developments/Updates
7.8.6 Biogen Competitive Strengths & Weaknesses
7.9 SunBio
7.9.1 SunBio Details
7.9.2 SunBio Major Business
7.9.3 SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.9.4 SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 SunBio Recent Developments/Updates
7.9.6 SunBio Competitive Strengths & Weaknesses
7.10 Qilu Pharmaceutical
7.10.1 Qilu Pharmaceutical Details
7.10.2 Qilu Pharmaceutical Major Business
7.10.3 Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.10.4 Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Qilu Pharmaceutical Recent Developments/Updates
7.10.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
7.11 Changchun Genescience Pharmaceutical
7.11.1 Changchun Genescience Pharmaceutical Details
7.11.2 Changchun Genescience Pharmaceutical Major Business
7.11.3 Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.11.4 Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Changchun Genescience Pharmaceutical Recent Developments/Updates
7.11.6 Changchun Genescience Pharmaceutical Competitive Strengths & Weaknesses
7.12 Xiamen Amoytop Biotech
7.12.1 Xiamen Amoytop Biotech Details
7.12.2 Xiamen Amoytop Biotech Major Business
7.12.3 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.12.4 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Xiamen Amoytop Biotech Recent Developments/Updates
7.12.6 Xiamen Amoytop Biotech Competitive Strengths & Weaknesses
7.13 Jiangsu Hengrui Pharmaceuticals
7.13.1 Jiangsu Hengrui Pharmaceuticals Details
7.13.2 Jiangsu Hengrui Pharmaceuticals Major Business
7.13.3 Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.13.4 Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
7.13.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
7.14 Hansoh Pharmaceuticak Group
7.14.1 Hansoh Pharmaceuticak Group Details
7.14.2 Hansoh Pharmaceuticak Group Major Business
7.14.3 Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.14.4 Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.14.5 Hansoh Pharmaceuticak Group Recent Developments/Updates
7.14.6 Hansoh Pharmaceuticak Group Competitive Strengths & Weaknesses
7.15 CSPC Baike (Shandong) Biopharmaceutical
7.15.1 CSPC Baike (Shandong) Biopharmaceutical Details
7.15.2 CSPC Baike (Shandong) Biopharmaceutical Major Business
7.15.3 CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.15.4 CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.15.5 CSPC Baike (Shandong) Biopharmaceutical Recent Developments/Updates
7.15.6 CSPC Baike (Shandong) Biopharmaceutical Competitive Strengths & Weaknesses
7.16 Xiamen Sano banger Biotechnology
7.16.1 Xiamen Sano banger Biotechnology Details
7.16.2 Xiamen Sano banger Biotechnology Major Business
7.16.3 Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.16.4 Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.16.5 Xiamen Sano banger Biotechnology Recent Developments/Updates
7.16.6 Xiamen Sano banger Biotechnology Competitive Strengths & Weaknesses
7.17 Lunan Pharmaceutical Group
7.17.1 Lunan Pharmaceutical Group Details
7.17.2 Lunan Pharmaceutical Group Major Business
7.17.3 Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.17.4 Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.17.5 Lunan Pharmaceutical Group Recent Developments/Updates
7.17.6 Lunan Pharmaceutical Group Competitive Strengths & Weaknesses
7.18 Xiamen Amoytop Biotech
7.18.1 Xiamen Amoytop Biotech Details
7.18.2 Xiamen Amoytop Biotech Major Business
7.18.3 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.18.4 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.18.5 Xiamen Amoytop Biotech Recent Developments/Updates
7.18.6 Xiamen Amoytop Biotech Competitive Strengths & Weaknesses
7.19 JenKem Technology
7.19.1 JenKem Technology Details
7.19.2 JenKem Technology Major Business
7.19.3 JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.19.4 JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.19.5 JenKem Technology Recent Developments/Updates
7.19.6 JenKem Technology Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Chain
8.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Upstream Analysis
8.2.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Core Raw Materials
8.2.2 Main Manufacturers of PEG-modified Drugs (Recombinant Proteins-Polypeptides) Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Mode
8.6 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Procurement Model
8.7 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Sales Model and Sales Channels
8.7.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Model
8.7.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Introduction
1.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Supply & Forecast
1.2.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value (2018 & 2022 & 2029)
1.2.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.2.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Pricing Trends (2018-2029)
1.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Region (Based on Production Site)
1.3.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Region (2018-2029)
1.3.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Region (2018-2029)
1.3.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2018-2029)
1.3.4 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.3.5 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.3.6 China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.3.7 Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Demand (2018-2029)
2.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption by Region
2.2.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption by Region (2018-2023)
2.2.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Forecast by Region (2024-2029)
2.3 United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.4 China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.5 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.6 Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.7 South Korea PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.8 ASEAN PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
2.9 India PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029)
3 WORLD PEG-MODIFIED DRUGS (RECOMBINANT PROTEINS-POLYPEPTIDES) MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Manufacturer (2018-2023)
3.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Manufacturer (2018-2023)
3.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Manufacturer (2018-2023)
3.4 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for PEG-modified Drugs (Recombinant Proteins-Polypeptides) in 2022
3.5.3 Global Concentration Ratios (CR8) for PEG-modified Drugs (Recombinant Proteins-Polypeptides) in 2022
3.6 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Overall Company Footprint Analysis
3.6.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Region Footprint
3.6.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Type Footprint
3.6.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Comparison
4.1.1 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Comparison
4.2.1 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Comparison
4.3.1 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers and Market Share, 2018-2023
4.4.1 United States Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value (2018-2023)
4.4.3 United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023)
4.5 China Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers and Market Share
4.5.1 China Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value (2018-2023)
4.5.3 China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023)
4.6 Rest of World Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Jinyouli
5.2.2 Xin Rui Bai
5.2.3 Shenlida
5.2.4 Jin Saizeng
5.2.5 Pegbin
5.2.6 Fulaimei
5.2.7 Aido
5.3 Market Segment by Type
5.3.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Type (2018-2029)
5.3.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type (2018-2029)
5.3.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Nonmyeloid Malignancy
6.2.2 Slow Growth in Children
6.2.3 Viral Hepatitis
6.2.4 Adult Type 2 Diabetes
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Application (2018-2029)
6.3.2 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application (2018-2029)
6.3.3 World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Merck Sharp & Dohme
7.1.1 Merck Sharp & Dohme Details
7.1.2 Merck Sharp & Dohme Major Business
7.1.3 Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.1.4 Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Merck Sharp & Dohme Recent Developments/Updates
7.1.6 Merck Sharp & Dohme Competitive Strengths & Weaknesses
7.2 Baxalta
7.2.1 Baxalta Details
7.2.2 Baxalta Major Business
7.2.3 Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.2.4 Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Baxalta Recent Developments/Updates
7.2.6 Baxalta Competitive Strengths & Weaknesses
7.3 Amgen
7.3.1 Amgen Details
7.3.2 Amgen Major Business
7.3.3 Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.3.4 Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Amgen Recent Developments/Updates
7.3.6 Amgen Competitive Strengths & Weaknesses
7.4 Roche
7.4.1 Roche Details
7.4.2 Roche Major Business
7.4.3 Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.4.4 Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Roche Recent Developments/Updates
7.4.6 Roche Competitive Strengths & Weaknesses
7.5 UCB S.A.
7.5.1 UCB S.A. Details
7.5.2 UCB S.A. Major Business
7.5.3 UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.5.4 UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 UCB S.A. Recent Developments/Updates
7.5.6 UCB S.A. Competitive Strengths & Weaknesses
7.6 Enzon
7.6.1 Enzon Details
7.6.2 Enzon Major Business
7.6.3 Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.6.4 Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Enzon Recent Developments/Updates
7.6.6 Enzon Competitive Strengths & Weaknesses
7.7 Horizon Pharma
7.7.1 Horizon Pharma Details
7.7.2 Horizon Pharma Major Business
7.7.3 Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.7.4 Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Horizon Pharma Recent Developments/Updates
7.7.6 Horizon Pharma Competitive Strengths & Weaknesses
7.8 Biogen
7.8.1 Biogen Details
7.8.2 Biogen Major Business
7.8.3 Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.8.4 Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Biogen Recent Developments/Updates
7.8.6 Biogen Competitive Strengths & Weaknesses
7.9 SunBio
7.9.1 SunBio Details
7.9.2 SunBio Major Business
7.9.3 SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.9.4 SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 SunBio Recent Developments/Updates
7.9.6 SunBio Competitive Strengths & Weaknesses
7.10 Qilu Pharmaceutical
7.10.1 Qilu Pharmaceutical Details
7.10.2 Qilu Pharmaceutical Major Business
7.10.3 Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.10.4 Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Qilu Pharmaceutical Recent Developments/Updates
7.10.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
7.11 Changchun Genescience Pharmaceutical
7.11.1 Changchun Genescience Pharmaceutical Details
7.11.2 Changchun Genescience Pharmaceutical Major Business
7.11.3 Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.11.4 Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Changchun Genescience Pharmaceutical Recent Developments/Updates
7.11.6 Changchun Genescience Pharmaceutical Competitive Strengths & Weaknesses
7.12 Xiamen Amoytop Biotech
7.12.1 Xiamen Amoytop Biotech Details
7.12.2 Xiamen Amoytop Biotech Major Business
7.12.3 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.12.4 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Xiamen Amoytop Biotech Recent Developments/Updates
7.12.6 Xiamen Amoytop Biotech Competitive Strengths & Weaknesses
7.13 Jiangsu Hengrui Pharmaceuticals
7.13.1 Jiangsu Hengrui Pharmaceuticals Details
7.13.2 Jiangsu Hengrui Pharmaceuticals Major Business
7.13.3 Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.13.4 Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
7.13.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
7.14 Hansoh Pharmaceuticak Group
7.14.1 Hansoh Pharmaceuticak Group Details
7.14.2 Hansoh Pharmaceuticak Group Major Business
7.14.3 Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.14.4 Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.14.5 Hansoh Pharmaceuticak Group Recent Developments/Updates
7.14.6 Hansoh Pharmaceuticak Group Competitive Strengths & Weaknesses
7.15 CSPC Baike (Shandong) Biopharmaceutical
7.15.1 CSPC Baike (Shandong) Biopharmaceutical Details
7.15.2 CSPC Baike (Shandong) Biopharmaceutical Major Business
7.15.3 CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.15.4 CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.15.5 CSPC Baike (Shandong) Biopharmaceutical Recent Developments/Updates
7.15.6 CSPC Baike (Shandong) Biopharmaceutical Competitive Strengths & Weaknesses
7.16 Xiamen Sano banger Biotechnology
7.16.1 Xiamen Sano banger Biotechnology Details
7.16.2 Xiamen Sano banger Biotechnology Major Business
7.16.3 Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.16.4 Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.16.5 Xiamen Sano banger Biotechnology Recent Developments/Updates
7.16.6 Xiamen Sano banger Biotechnology Competitive Strengths & Weaknesses
7.17 Lunan Pharmaceutical Group
7.17.1 Lunan Pharmaceutical Group Details
7.17.2 Lunan Pharmaceutical Group Major Business
7.17.3 Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.17.4 Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.17.5 Lunan Pharmaceutical Group Recent Developments/Updates
7.17.6 Lunan Pharmaceutical Group Competitive Strengths & Weaknesses
7.18 Xiamen Amoytop Biotech
7.18.1 Xiamen Amoytop Biotech Details
7.18.2 Xiamen Amoytop Biotech Major Business
7.18.3 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.18.4 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.18.5 Xiamen Amoytop Biotech Recent Developments/Updates
7.18.6 Xiamen Amoytop Biotech Competitive Strengths & Weaknesses
7.19 JenKem Technology
7.19.1 JenKem Technology Details
7.19.2 JenKem Technology Major Business
7.19.3 JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
7.19.4 JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.19.5 JenKem Technology Recent Developments/Updates
7.19.6 JenKem Technology Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Chain
8.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Upstream Analysis
8.2.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Core Raw Materials
8.2.2 Main Manufacturers of PEG-modified Drugs (Recombinant Proteins-Polypeptides) Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Mode
8.6 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Procurement Model
8.7 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Sales Model and Sales Channels
8.7.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Model
8.7.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Region (2018-2023) & (USD Million)
Table 3. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Region (2024-2029) & (USD Million)
Table 4. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Region (2018-2023)
Table 5. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Region (2024-2029)
Table 6. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Region (2018-2023) & (K Units)
Table 7. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Region (2024-2029) & (K Units)
Table 8. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Region (2018-2023)
Table 9. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Region (2024-2029)
Table 10. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2024-2029) & (US$/Unit)
Table 12. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Major Market Trends
Table 13. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption by Region (2018-2023) & (K Units)
Table 15. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key PEG-modified Drugs (Recombinant Proteins-Polypeptides) Producers in 2022
Table 18. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key PEG-modified Drugs (Recombinant Proteins-Polypeptides) Producers in 2022
Table 20. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Company Evaluation Quadrant
Table 22. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Site of Key Manufacturer
Table 24. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Type Footprint
Table 25. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Application Footprint
Table 26. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Competitive Factors
Table 27. PEG-modified Drugs (Recombinant Proteins-Polypeptides) New Entrant and Capacity Expansion Plans
Table 28. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Mergers & Acquisitions Activity
Table 29. United States VS China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share (2018-2023)
Table 37. China Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share (2018-2023)
Table 42. Rest of World Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share (2018-2023)
Table 47. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Type (2018-2023) & (K Units)
Table 49. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Type (2024-2029) & (K Units)
Table 50. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type (2018-2023) & (USD Million)
Table 51. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type (2024-2029) & (USD Million)
Table 52. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Application (2018-2023) & (K Units)
Table 56. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Application (2024-2029) & (K Units)
Table 57. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application (2018-2023) & (USD Million)
Table 58. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application (2024-2029) & (USD Million)
Table 59. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Merck Sharp & Dohme Basic Information, Manufacturing Base and Competitors
Table 62. Merck Sharp & Dohme Major Business
Table 63. Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 64. Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Merck Sharp & Dohme Recent Developments/Updates
Table 66. Merck Sharp & Dohme Competitive Strengths & Weaknesses
Table 67. Baxalta Basic Information, Manufacturing Base and Competitors
Table 68. Baxalta Major Business
Table 69. Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 70. Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Baxalta Recent Developments/Updates
Table 72. Baxalta Competitive Strengths & Weaknesses
Table 73. Amgen Basic Information, Manufacturing Base and Competitors
Table 74. Amgen Major Business
Table 75. Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 76. Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Amgen Recent Developments/Updates
Table 78. Amgen Competitive Strengths & Weaknesses
Table 79. Roche Basic Information, Manufacturing Base and Competitors
Table 80. Roche Major Business
Table 81. Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 82. Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Roche Recent Developments/Updates
Table 84. Roche Competitive Strengths & Weaknesses
Table 85. UCB S.A. Basic Information, Manufacturing Base and Competitors
Table 86. UCB S.A. Major Business
Table 87. UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 88. UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. UCB S.A. Recent Developments/Updates
Table 90. UCB S.A. Competitive Strengths & Weaknesses
Table 91. Enzon Basic Information, Manufacturing Base and Competitors
Table 92. Enzon Major Business
Table 93. Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 94. Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Enzon Recent Developments/Updates
Table 96. Enzon Competitive Strengths & Weaknesses
Table 97. Horizon Pharma Basic Information, Manufacturing Base and Competitors
Table 98. Horizon Pharma Major Business
Table 99. Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 100. Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Horizon Pharma Recent Developments/Updates
Table 102. Horizon Pharma Competitive Strengths & Weaknesses
Table 103. Biogen Basic Information, Manufacturing Base and Competitors
Table 104. Biogen Major Business
Table 105. Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 106. Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Biogen Recent Developments/Updates
Table 108. Biogen Competitive Strengths & Weaknesses
Table 109. SunBio Basic Information, Manufacturing Base and Competitors
Table 110. SunBio Major Business
Table 111. SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 112. SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. SunBio Recent Developments/Updates
Table 114. SunBio Competitive Strengths & Weaknesses
Table 115. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 116. Qilu Pharmaceutical Major Business
Table 117. Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 118. Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Qilu Pharmaceutical Recent Developments/Updates
Table 120. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 121. Changchun Genescience Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 122. Changchun Genescience Pharmaceutical Major Business
Table 123. Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 124. Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Changchun Genescience Pharmaceutical Recent Developments/Updates
Table 126. Changchun Genescience Pharmaceutical Competitive Strengths & Weaknesses
Table 127. Xiamen Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 128. Xiamen Amoytop Biotech Major Business
Table 129. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 130. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Xiamen Amoytop Biotech Recent Developments/Updates
Table 132. Xiamen Amoytop Biotech Competitive Strengths & Weaknesses
Table 133. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 134. Jiangsu Hengrui Pharmaceuticals Major Business
Table 135. Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 136. Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 137. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 138. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 139. Hansoh Pharmaceuticak Group Basic Information, Manufacturing Base and Competitors
Table 140. Hansoh Pharmaceuticak Group Major Business
Table 141. Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 142. Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 143. Hansoh Pharmaceuticak Group Recent Developments/Updates
Table 144. Hansoh Pharmaceuticak Group Competitive Strengths & Weaknesses
Table 145. CSPC Baike (Shandong) Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 146. CSPC Baike (Shandong) Biopharmaceutical Major Business
Table 147. CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 148. CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 149. CSPC Baike (Shandong) Biopharmaceutical Recent Developments/Updates
Table 150. CSPC Baike (Shandong) Biopharmaceutical Competitive Strengths & Weaknesses
Table 151. Xiamen Sano banger Biotechnology Basic Information, Manufacturing Base and Competitors
Table 152. Xiamen Sano banger Biotechnology Major Business
Table 153. Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 154. Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 155. Xiamen Sano banger Biotechnology Recent Developments/Updates
Table 156. Xiamen Sano banger Biotechnology Competitive Strengths & Weaknesses
Table 157. Lunan Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 158. Lunan Pharmaceutical Group Major Business
Table 159. Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 160. Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 161. Lunan Pharmaceutical Group Recent Developments/Updates
Table 162. Lunan Pharmaceutical Group Competitive Strengths & Weaknesses
Table 163. Xiamen Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 164. Xiamen Amoytop Biotech Major Business
Table 165. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 166. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 167. Xiamen Amoytop Biotech Recent Developments/Updates
Table 168. JenKem Technology Basic Information, Manufacturing Base and Competitors
Table 169. JenKem Technology Major Business
Table 170. JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 171. JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 172. Global Key Players of PEG-modified Drugs (Recombinant Proteins-Polypeptides) Upstream (Raw Materials)
Table 173. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Customers
Table 174. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Distributors
List of Figure
Figure 1. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Picture
Figure 2. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 5. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price (2018-2029) & (US$/Unit)
Figure 6. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Region (2018-2029)
Figure 7. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Region (2018-2029)
Figure 8. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 9. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 10. China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 11. Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 12. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 15. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Market Share by Region (2018-2029)
Figure 16. United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 17. China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 18. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 19. Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 20. South Korea PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 21. ASEAN PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 22. India PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of PEG-modified Drugs (Recombinant Proteins-Polypeptides) by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for PEG-modified Drugs (Recombinant Proteins-Polypeptides) Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for PEG-modified Drugs (Recombinant Proteins-Polypeptides) Markets in 2022
Figure 26. United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share 2022
Figure 30. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share 2022
Figure 31. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share 2022
Figure 32. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Type in 2022
Figure 34. Jinyouli
Figure 35. Xin Rui Bai
Figure 36. Shenlida
Figure 37. Jin Saizeng
Figure 38. Pegbin
Figure 39. Fulaimei
Figure 40. Aido
Figure 41. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Type (2018-2029)
Figure 42. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Type (2018-2029)
Figure 43. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2029) & (US$/Unit)
Figure 44. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 45. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Application in 2022
Figure 46. Nonmyeloid Malignancy
Figure 47. Slow Growth in Children
Figure 48. Viral Hepatitis
Figure 49. Adult Type 2 Diabetes
Figure 50. Others
Figure 51. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Application (2018-2029)
Figure 52. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Application (2018-2029)
Figure 53. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2029) & (US$/Unit)
Figure 54. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Chain
Figure 55. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Procurement Model
Figure 56. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Model
Figure 57. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Channels, Direct Sales, and Distribution
Figure 58. Methodology
Figure 59. Research Process and Data Source
Table 1. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Region (2018-2023) & (USD Million)
Table 3. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Region (2024-2029) & (USD Million)
Table 4. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Region (2018-2023)
Table 5. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Region (2024-2029)
Table 6. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Region (2018-2023) & (K Units)
Table 7. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Region (2024-2029) & (K Units)
Table 8. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Region (2018-2023)
Table 9. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Region (2024-2029)
Table 10. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2024-2029) & (US$/Unit)
Table 12. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Major Market Trends
Table 13. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption by Region (2018-2023) & (K Units)
Table 15. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key PEG-modified Drugs (Recombinant Proteins-Polypeptides) Producers in 2022
Table 18. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key PEG-modified Drugs (Recombinant Proteins-Polypeptides) Producers in 2022
Table 20. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Company Evaluation Quadrant
Table 22. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Site of Key Manufacturer
Table 24. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Type Footprint
Table 25. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Application Footprint
Table 26. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Competitive Factors
Table 27. PEG-modified Drugs (Recombinant Proteins-Polypeptides) New Entrant and Capacity Expansion Plans
Table 28. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Mergers & Acquisitions Activity
Table 29. United States VS China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share (2018-2023)
Table 37. China Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share (2018-2023)
Table 42. Rest of World Based PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share (2018-2023)
Table 47. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Type (2018-2023) & (K Units)
Table 49. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Type (2024-2029) & (K Units)
Table 50. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type (2018-2023) & (USD Million)
Table 51. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type (2024-2029) & (USD Million)
Table 52. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Application (2018-2023) & (K Units)
Table 56. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production by Application (2024-2029) & (K Units)
Table 57. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application (2018-2023) & (USD Million)
Table 58. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application (2024-2029) & (USD Million)
Table 59. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Merck Sharp & Dohme Basic Information, Manufacturing Base and Competitors
Table 62. Merck Sharp & Dohme Major Business
Table 63. Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 64. Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Merck Sharp & Dohme Recent Developments/Updates
Table 66. Merck Sharp & Dohme Competitive Strengths & Weaknesses
Table 67. Baxalta Basic Information, Manufacturing Base and Competitors
Table 68. Baxalta Major Business
Table 69. Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 70. Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Baxalta Recent Developments/Updates
Table 72. Baxalta Competitive Strengths & Weaknesses
Table 73. Amgen Basic Information, Manufacturing Base and Competitors
Table 74. Amgen Major Business
Table 75. Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 76. Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Amgen Recent Developments/Updates
Table 78. Amgen Competitive Strengths & Weaknesses
Table 79. Roche Basic Information, Manufacturing Base and Competitors
Table 80. Roche Major Business
Table 81. Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 82. Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Roche Recent Developments/Updates
Table 84. Roche Competitive Strengths & Weaknesses
Table 85. UCB S.A. Basic Information, Manufacturing Base and Competitors
Table 86. UCB S.A. Major Business
Table 87. UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 88. UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. UCB S.A. Recent Developments/Updates
Table 90. UCB S.A. Competitive Strengths & Weaknesses
Table 91. Enzon Basic Information, Manufacturing Base and Competitors
Table 92. Enzon Major Business
Table 93. Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 94. Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Enzon Recent Developments/Updates
Table 96. Enzon Competitive Strengths & Weaknesses
Table 97. Horizon Pharma Basic Information, Manufacturing Base and Competitors
Table 98. Horizon Pharma Major Business
Table 99. Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 100. Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Horizon Pharma Recent Developments/Updates
Table 102. Horizon Pharma Competitive Strengths & Weaknesses
Table 103. Biogen Basic Information, Manufacturing Base and Competitors
Table 104. Biogen Major Business
Table 105. Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 106. Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Biogen Recent Developments/Updates
Table 108. Biogen Competitive Strengths & Weaknesses
Table 109. SunBio Basic Information, Manufacturing Base and Competitors
Table 110. SunBio Major Business
Table 111. SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 112. SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. SunBio Recent Developments/Updates
Table 114. SunBio Competitive Strengths & Weaknesses
Table 115. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 116. Qilu Pharmaceutical Major Business
Table 117. Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 118. Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Qilu Pharmaceutical Recent Developments/Updates
Table 120. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 121. Changchun Genescience Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 122. Changchun Genescience Pharmaceutical Major Business
Table 123. Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 124. Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Changchun Genescience Pharmaceutical Recent Developments/Updates
Table 126. Changchun Genescience Pharmaceutical Competitive Strengths & Weaknesses
Table 127. Xiamen Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 128. Xiamen Amoytop Biotech Major Business
Table 129. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 130. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Xiamen Amoytop Biotech Recent Developments/Updates
Table 132. Xiamen Amoytop Biotech Competitive Strengths & Weaknesses
Table 133. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 134. Jiangsu Hengrui Pharmaceuticals Major Business
Table 135. Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 136. Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 137. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 138. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 139. Hansoh Pharmaceuticak Group Basic Information, Manufacturing Base and Competitors
Table 140. Hansoh Pharmaceuticak Group Major Business
Table 141. Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 142. Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 143. Hansoh Pharmaceuticak Group Recent Developments/Updates
Table 144. Hansoh Pharmaceuticak Group Competitive Strengths & Weaknesses
Table 145. CSPC Baike (Shandong) Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 146. CSPC Baike (Shandong) Biopharmaceutical Major Business
Table 147. CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 148. CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 149. CSPC Baike (Shandong) Biopharmaceutical Recent Developments/Updates
Table 150. CSPC Baike (Shandong) Biopharmaceutical Competitive Strengths & Weaknesses
Table 151. Xiamen Sano banger Biotechnology Basic Information, Manufacturing Base and Competitors
Table 152. Xiamen Sano banger Biotechnology Major Business
Table 153. Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 154. Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 155. Xiamen Sano banger Biotechnology Recent Developments/Updates
Table 156. Xiamen Sano banger Biotechnology Competitive Strengths & Weaknesses
Table 157. Lunan Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 158. Lunan Pharmaceutical Group Major Business
Table 159. Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 160. Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 161. Lunan Pharmaceutical Group Recent Developments/Updates
Table 162. Lunan Pharmaceutical Group Competitive Strengths & Weaknesses
Table 163. Xiamen Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 164. Xiamen Amoytop Biotech Major Business
Table 165. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 166. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 167. Xiamen Amoytop Biotech Recent Developments/Updates
Table 168. JenKem Technology Basic Information, Manufacturing Base and Competitors
Table 169. JenKem Technology Major Business
Table 170. JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 171. JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 172. Global Key Players of PEG-modified Drugs (Recombinant Proteins-Polypeptides) Upstream (Raw Materials)
Table 173. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Customers
Table 174. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Distributors
List of Figure
Figure 1. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Picture
Figure 2. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 5. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price (2018-2029) & (US$/Unit)
Figure 6. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Region (2018-2029)
Figure 7. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Region (2018-2029)
Figure 8. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 9. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 10. China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 11. Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production (2018-2029) & (K Units)
Figure 12. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 15. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Market Share by Region (2018-2029)
Figure 16. United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 17. China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 18. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 19. Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 20. South Korea PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 21. ASEAN PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 22. India PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of PEG-modified Drugs (Recombinant Proteins-Polypeptides) by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for PEG-modified Drugs (Recombinant Proteins-Polypeptides) Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for PEG-modified Drugs (Recombinant Proteins-Polypeptides) Markets in 2022
Figure 26. United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share 2022
Figure 30. China Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share 2022
Figure 31. Rest of World Based Manufacturers PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share 2022
Figure 32. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Type in 2022
Figure 34. Jinyouli
Figure 35. Xin Rui Bai
Figure 36. Shenlida
Figure 37. Jin Saizeng
Figure 38. Pegbin
Figure 39. Fulaimei
Figure 40. Aido
Figure 41. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Type (2018-2029)
Figure 42. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Type (2018-2029)
Figure 43. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2029) & (US$/Unit)
Figure 44. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 45. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Application in 2022
Figure 46. Nonmyeloid Malignancy
Figure 47. Slow Growth in Children
Figure 48. Viral Hepatitis
Figure 49. Adult Type 2 Diabetes
Figure 50. Others
Figure 51. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Market Share by Application (2018-2029)
Figure 52. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Value Market Share by Application (2018-2029)
Figure 53. World PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2029) & (US$/Unit)
Figure 54. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industry Chain
Figure 55. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Procurement Model
Figure 56. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Model
Figure 57. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Channels, Direct Sales, and Distribution
Figure 58. Methodology
Figure 59. Research Process and Data Source
